Viewing nowPoshuvet Tablet 5 mg (Dapagliflozin Propanediol Monohydrate)
Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication
Genewon Science Co., Ltd.

MFDS item code 202204690 · Approved 2022.12.29 · Insurance code 671707230
Improvement of glycemic control in type 2 diabetes mellitus; treatment of chronic heart failure and chronic kidney disease
This medication is used to help control blood sugar in patients with type 2 diabetes. Additionally, it contributes to maintaining health by reducing the risk of death and hospitalization in patients with chronic heart failure. In patients with chronic kidney disease, it helps reduce the risks associated with declining kidney function. This medication is used in conjunction with other standard treatment methods for each condition to enhance therapeutic effects. Overall, it is an effective drug for blood sugar management and improvement of cardiovascular and kidney health.
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no previous experience of antidiabetic drug treatment who are receiving this medicine in combination with metformin, the recommended initial dose is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - eGFR less than 25 mL/min/1.73m2: Initiation of this medicine is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, an initial dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be taken orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.
This medication should not be used by individuals with allergies to this medication's active ingredients or additives. Patients with type 1 diabetes or diabetic ketoacidosis should also not use this medicament. Patients with genetic lactose intolerance, such as galactose intolerance or Lapp lactase deficiency, and glucose-galactose malabsorption should not take this medication. Patients on dialysis should not use this medication. Caution should be exercised when using this medication in patients with reduced fluid volume or poor kidney function. This medication may lower blood pressure or reduce blood volume; thus, symptomatic hypotension or changes in kidney function may occur, requiring careful monitoring of fluid volume and kidney function before and during administration. Particularly, in patients with moderate to severe reduction in kidney function, blood sugar control effectiveness may decrease, and it is not recommended for patients with very low kidney function. While taking this medication, genital infections or urinary tract infections may occur; thus, immediate treatment should be sought if symptoms arise. When used with drugs that pose a risk of hypoglycemia, hypoglycemic symptoms may occur, necessitating adjustments to the doses of insulin or sulfonylureas. If symptoms of dehydration or hypotension occur due to reduced fluid volume, consultation with healthcare providers is necessary, and the use of this medication may need to be temporarily discontinued if necessary. This medication can cause a serious metabolic disturbance known as diabetic ketoacidosis; seek medical attention immediately if symptoms such as nausea, vomiting, abdominal pain, or difficulty breathing occur. Women who are pregnant or breastfeeding are advised not to use this medication, and if pregnancy is confirmed, administration should be stopped. Elderly patients or patients with reduced kidney function require special caution and should undergo regular kidney function testing during the use of this medication. This medication does not significantly impair the ability to operate vehicles or machinery, but caution is needed when taken with medications that pose a risk of hypoglycemia. Finally, this medication should be kept out of reach of children and stored in its original container to maintain quality.
Vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal gangrene, hypoglycemia, decreased fluid volume, thirst, diabetic ketoacidosis, dizziness, constipation, dry mouth, back pain, dysuria, polyuria, nocturia, interstitial nephritis, vulvar itching, genital itching, increased hematocrit, initial treatment-related decrease in kidney creatinine clearance, dyslipidemia, initial treatment-related increase in serum creatinine, increased blood urea, weight loss, acute pyelonephritis, rash, angioedema, asthenia, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina pectoris, myocardial infarction, biliary stones, cholangitis, alcoholic cirrhosis, depression, suicide attempt, pancreatic cancer, anaphylactic reaction, chest pain, paresthesia, cerebral infarction, nerve compression, urosepsis, pyelonephritis, ligament sprain, keratitis, dry eye, eye pain, retinal disorder, decreased vision, blepharitis, cataract, conjunctival edema, allergic conjunctivitis, conjunctivitis, double vision, eyelid edema, ocular hypertension, visual impairment, vitreous floaters, oropharyngeal pain, allergic rhinitis, asthma, voice disorder, epistaxis, sleep apnea syndrome, wheezing, arteriosclerosis, flushing, peripheral coldness, varices, vascular headache, orthostatic hypotension, atrial fibrillation, diastolic dysfunction, palpitations, anxiety disorder, enuresis, auditory hallucinations, sleep disorder, insomnia, fatty liver, gallbladder polyps, dizziness, anal genital warts, adenoma, neuroma, pituitary neoplasm of unspecified type, male gonadal insufficiency, thyroid cyst, thyroid nodule, food allergy, polycythemia, dyspepsia, nausea, diarrhea, vomiting, urinary retention, abnormal urination, increased alanine aminotransferase, increased aspartate aminotransferase, weight gain, decreased appetite, hypersomnia, dysgeusia, headache, nasopharyngitis, upper respiratory infection, chest discomfort, peripheral edema, general edema, hunger, vaginal discharge, menstrual irregularities, itching, urticaria, cold sweat, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, contusion, orbital fracture, foot fracture, gastrointestinal foreign body, laceration, ligament rupture, limb injury, skin abrasion, tendon rupture, thoracic spine fracture, tibial fracture, dental injury, diabetic retinopathy, cough, shortness of breath, palpitations, tinnitus
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture and kept at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication's efficacy over time.
Yellow, double convex, round film-coated tablet
28 tablets (14 tablets/PTP × 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowDapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication
Genewon Science Co., Ltd.
Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.
Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.
Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Il Sung IS Co., Ltd.
Dapagliflozin Propanediol Hydrate
Prescription medication
Optus Pharmaceutical Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Aprogen Biologics Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Il Yang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.